TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03273907

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cataract surgery
Description: Cataract surgery, followed by implantation of the CyPass Micro-Stent in one eye (the study eye) at the surgery visit
Study: NCT03540420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: atezolizumab 1200 mg intravenous every 3 weeks in 12 months
Study: NCT02213614

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lithium Water
Description: Supply daily doses of Lithium water in form bottled mineral water
Study: NCT01895699

Intervention type: OTHER
Group type: OTHER
Intervention: Contrast agent

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Contrast agent
Study: NCT03674034

Intervention type: OTHER
Intervention: CTscan and MRI images
Description: CTscan and MRI images segmented according to procedures previously developed by GRAMFC

Intervention type: OTHER
Intervention: CTscan and MRI images
Description: CTscan and MRI images segmented according to procedures previously developed by GRAMFC
Study: NCT02213614

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: placebo: spring mineral water
Description: Drink spring natural water a placebo 3 times a day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: natural spring water
Description: A group will drink natural spring water for 4 months
Study: NCT03674034

Intervention type: OTHER
Intervention: CTscan and MRI images
Description: CTscan and MRI images segmented according to procedures previously developed by GRAMFC
Study: NCT00296036

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: pyridoxine hydrochloride
Description: Given orally

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: pyridoxine hydrochloride
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: urea/lactic acid-based topical cream
Description: Applied topically

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: urea/lactic acid-based topical cream
Description: Applied topically

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: urea/lactic acid-based topical cream
Description: Applied topically

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: Given orally or applied topically

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: Given orally or applied topically

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given orally or applied topically

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given orally or applied topically
Study: NCT01189331

Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: CT coronary angiography and computational fluid dynamics
Description: Evaluate coronary blood flow dynamics by CT coronary angiography and computational fluid dynamics
Study: NCT03688360

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: . Each intervention will contain a 60-minute psycho-education session (PE) and two 60-minute exposure sessions (EX), conducted by a mental health professional together with a master student in psychology, who are both weekly supervised by a CBT certified psychologist. In the first (PE) session, participants learn about anxiety, specific phobias and exposure. During this session they will create a fear hierarchy, formulate their cognition about the feared object or situation and determine what they want to achieve during treatment (e.g. goal situation). The next two sessions consist of exposure exercises.
Study: NCT03195504

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HFNC
Description: High flow nasal oxygen (60 l) under GA

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CON (control)
Description: Standard oxygen (10-15 l) under GA
Study: NCT02266563

Intervention type: DRUG
Intervention: Amyvid PET Scan
Description: A thin line will be inserted into a vein in one arm for the injection of the tracer. Subjects will begin the Amyvid PET scan 50-60 minutes after the injection of the tracer, and scanned for about 20 minutes.
Study: NCT04553861

Intervention type: DEVICE
Intervention: Galaxy Watch Active2
Description: Every 1 hour by subject (on-demand) from 7 AM to 10 PM and every 5 minutes (automatic) from 10 PM to 7 AM
Study: NCT04446000

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CSL730
Description: solution for injection and infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CSL730
Description: solution for injection and infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CSL730
Description: solution for injection and infusion
Study: NCT02266563

Intervention type: DRUG
Intervention: Amyvid PET Scan
Description: A thin line will be inserted into a vein in one arm for the injection of the tracer. Subjects will begin the Amyvid PET scan 50-60 minutes after the injection of the tracer, and scanned for about 20 minutes.

Intervention type: DRUG
Intervention: Amyvid PET Scan
Description: A thin line will be inserted into a vein in one arm for the injection of the tracer. Subjects will begin the Amyvid PET scan 50-60 minutes after the injection of the tracer, and scanned for about 20 minutes.

Intervention type: DRUG
Intervention: T807 PET scan
Description: Scanning will begin 80 minutes after the injection of the tracer, and last for about 20 minutes.

Intervention type: DRUG
Intervention: T807 PET scan
Description: Scanning will begin 80 minutes after the injection of the tracer, and last for about 20 minutes.

Intervention type: DRUG
Intervention: T807 PET scan
Description: Scanning will begin 80 minutes after the injection of the tracer, and last for about 20 minutes.
Study: NCT03018158

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: denture wear.
Description: MR Imaging was collected with or without denture wear.
Study: NCT02472249

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: CT perfusion
Description: Two dynamic CT perfusion acquisitions of the whole liver will be performed with a 320-detectors CT, prior and after to the norepinephrine injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine intra-arteriel/hepatic
Description: A small dose (24 ug) of norepinephrine will be injected in the hepatic artery over 10 seconds. The half-life of the drug is 90 seconds..
Study: NCT00186628

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total lymphoid irradiation
Description: Total lymphoid irradiation (TLI) administered at 80cGy for 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 375 mg/m2 administered as an intravenous (IV) infusion once weekly for 4 doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-thymoglobulin, rabbit (ATG, rabbit ATG)
Description: Rabbit anti-thymoglobulin (ATG) administered from Day -11 through Day -7 (5 doses) at 1.5 mg/kg/day, for a total dose of 7.5 mg/kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Cyclosporine (CSP) administered orally at 6.25 mg/kg twice-a-day (BID) from Day -3 until through Day +56 post-peripheral blood progenitor cell (PBPC) infusion. Dose may be adjusted to maintain a therapeutic level of cyclosporine, or in response to renal insufficiency. If at Day +56, chimerism assessment demonstrates \> 40% donor cells in the CD3+ lineage, and the patient is without evidence of GvHD, then cyclosporine taper will begin (6% reduction per week).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenylate mofetil
Description: Mycophenylate mofetil (MMF) will be administered at 15 mg/kg po Day 0, at 5 to 10 hours after mobilized PBPC infusion is complete
Study: NCT01745705

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cervical Spine Manipulation

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Manual Contact
Study: NCT04446000

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A solution matching the excipient profile of CSL730 without the active substance
Study: NCT03533868

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Point-of-care viral load monitoring test
Description: For enumerating viral load for patients in the POC arm, we will use the Cepheid Xpert® HIV-1 Viral Load test, a quantitative assay with a quantification range of 40 to 10,000,000 copies/mL. Based on the GeneXpert® technology, Xpert HIV-1 VL automates the test process, including RNA extraction, purification, reverse transcription and cDNA real-time quantitation in one fully integrated cartridge. The pre-loaded disposable single-use cartridges provide a visual read-out within 90 minutes. The assay requires 1 mL of plasma using a precision pipette (1.2 mL using a transfer pipette).
Study: NCT00186628

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Filgrastim provided as needed for neutrophil support

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granisetron
Description: Granisetron administered as an anti-nausea agent (anti-emetic) at 1 mg orally 30 to 60 minutes before TLI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solumedrol
Description: Solumedrol, an anti-inflammatory glucocorticoid containing methylprednisolone sodium succinate, administered at 1 mg/kg as a premedication for anti-thymoglobulin (ATG)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Acetaminophen administered orally at 650 mg 1 hour prior to infusion of PBPC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: Diphenhydramine administered by intravenous infusion at 50 mg 1 hour prior to infusion of PBPC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: Hydrocortisone administered by intravenous infusion at 100 mg 1 hour prior to infusion of PBPC
Study: NCT04403919

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Closure: Knee
Description: Traditional closure will consist of arthrotomy (deep layer) closed with figure of eight number 1 vicryl plus followed by closure of the intermediate layer with 0 Vicryl plus. The intermediate layer will be performed at surgeon's discretion especially in thin patients. Subdermal layer with 2-0 vicryl suture followed by subcuticular 3-0 monofilament suture (monocryl PLUS, Ethicon; Johnson \& Johnson) and Dermabond advanced.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Barbed suture closure: Knee
Description: The barbed suture closure will consist of number 2 Stratafix symmetric PDS PLUS for the arthrotomy, intermediate layer will be performed at surgeon's discretion in thin patients, if performed will entail stratafix spiral, subdermal 2-0 stratafix spiral monocryl plus. Followed by subcuticular 3-0 stratafix spiral monocryl plus suture and Dermabond advance.
Study: NCT04599127

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobilization with movement
Description: The physical therapist will adjust the active movement of the shoulder joint during the arm elevation or abduction and shoulder external rotation

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Conventional physical therapy
Description: The exercise is tailor-made and each participant will be performing some of the exercises based on the list that physical therapist prescription
Study: NCT01000831

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: adjuvanted Arepanrix
Description: Two doses of adjuvanted Arepanrix vaccine given 3 weeks apart
Study: NCT01552200

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Group A-Standard Colonoscopy, then NaviAid™ G-Eye procedure
Description: Standard Colonoscopy,NaviAid™ G-Eye procedure
Study: NCT04599127

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional physical therapy
Description: The exercise is tailor-made and each participant will be performing some of the exercises based on the list that physical therapist prescription
Study: NCT03748849

Intervention type: PROCEDURE
Intervention: Physiotherapy
Study: NCT03485053

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IOP Injection / MPB-1514
Description: Dilute with 5% Dextrose solution (D5W)
Study: NCT04613674

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab Plus Chemotherapy
Description: camrelizumab+chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo+chemotherapy
Description: placebo+chemotherapy
Study: NCT04403919

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Closure: Hip
Description: 1. The capsule will be closed with Vicryl Plus number 1~2. Deep fascia with figure of eight interrupted number 1 braided absorbable suture (Vicryl plus, Ethicon; Johnson \&Johnson, Somerville, NJ)~3. Subdermal fat layer simple interrupted knots using number 2-0 braided absorbable sutures (Vicryl plus)~4. Subcuticular 3-0 monofilament suture (monocryl plus , Ethicon; Johnson \& Johnson)~5. followed by the use of skin adhesive (Dermabond Advanced, Ethicon; Johnson \&Johnson).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Barbed suture closure: Hip
Description: 1. The capsule will be closed with stratafix symmetric PDS Plus~2. Deep fascia will be closed with Stratafix Symmetric PDS Plus (Stratafix symmetric PDS plus, Ethicon; Johnson \&Johnson, Somerville, NJ)~3. Subdermal layer with running number 2-0 barbed suture (stratafix spiral monocryl plus, Ethicon; Johnson \& Johnson, Somerville, NJ)~4. Subcuticular suture with stratafix spiral monocryl plus, Ethicon~5. followed by the use of skin adhesive (Dermabond advanced, Ethicon; Johnson \&Johnson).
Study: NCT01552200

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group B-NaviAid™ G-Eye procedure, then Standard Colonoscopy
Description: G-Eye procedure, Standard Colonoscopy
Study: NCT03102983

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI functional
Description: vowels records and MRI session
Study: NCT01162551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus and Methotrexate
Description: Single Arm Efficacy Trial:~Sirolimus: Oral bolus on day 1, then daily oral dose days 2-28. Dose will be altered to maintain a sirolimus trough level between ≥ 8 and ≤ 13. Trough levels will be checked weekly.~Methotrexate: Oral 20 mg/m2/week on Days 2, 9, 16, 23.~One cycle is 28 days.
Study: NCT03602443

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LSVT®BIG Intervention
Description: Participants will complete LSVT®BIG intervention which consists of 16 one-hour sessions on 4 consecutive days for 4 weeks, and a home program component.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: LSVT®BIG Intervention
Description: Participants will complete LSVT®BIG intervention which consists of 16 one-hour sessions on 4 consecutive days for 4 weeks, and a home program component.
Study: NCT03745768

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent Theta Burst Stimulation
Description: Intermittent theta burst stimulation delivered to the dorsolateral prefrontal cortex on the left and right sides of the brain for 6 weeks.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham stimulation
Description: Sham stimulation delivered to the dorsolateral prefrontal cortex on the left and right sides of the brain for 6 weeks.
Study: NCT00893841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: quetiapine (Seroquel) XR
Description: tablets and caplets, take with liquid before bedtime

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: quetiapine (Seroquel) XR
Description: tablets and caplets, take with liquid before bedtime

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: quetiapine (Seroquel) XR
Description: tablets, take with liquid before bedtime

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT02019693

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INC280
Description: Supplied by Novartis as film-coated tablet for oral use.
Study: NCT03339908

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thalamotomy by gamma Knife radiosurgery
Description: The surgical procedure consists of a very partial radiation of the brain with stereotaxic precision
Study: NCT03758066

Intervention type: DEVICE
Group type: OTHER
Intervention: PlusCare
Description: PlusCare is a mobile application designed to be used by youth and young adults with HIV and case managers.
Study: NCT01216761

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iodine tincture
Description: Iodine tincture (2% iodine and 2% sodium iodide diluted in 50% ethanol) packaged in a single 0.67 mL Sepp applicator (Enturia, Leewood KS)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iodine tincture
Description: Iodine tincture (2% iodine and 2% sodium iodide diluted in 50% ethanol) packaged in a single 0.67 mL Sepp applicator (Enturia, Leewood KS)
Study: NCT01725464

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: oxygen cannular
Description: Patient receives oxygen supplementation 5 LPM via oxygen cannular for 120 minutes after the operative
Study: NCT00809939

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 17 alfa hydroxyprogesterone caproate
Description: weekly injection of 250 mg until 34 weeks gestation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: natural progesterone
Description: previous preterm delivery, treatment with daily vaginal progesterone 200 mg until 34 weeks gestation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 17 alfa hydroxyprogesterone caproate
Description: weekly injection, 250 mg until 34 weeks gestation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vaginal progesterone
Description: daily vaginal progesterone 200 mg until 34 weeks gestation.
Study: NCT02309996

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supervisor Training Program
Study: NCT01777750

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EMCOOLS flex pad; Philips Innercool RTx
Description: Surface cooling with EMCOOLS flex pads (out-of-hospital); Infusion of 1000ml to 2000ml of cold saline (out-of-hospital); central-venous cooling (Philips Inntercool RTx)
Study: NCT03144518

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Positive Affect Intervention
Description: See Previous Description

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neutral Control Intervention
Description: See Previous Description

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Northern Hemisphere Influenza Vaccine 2017/18 (Delivered as part of Standard Care)
Description: Northern Hemisphere Influenza Vaccine 2017/18 (Delivered as part of Standard Care)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Northern Hemisphere Influenza Vaccine 2017/18 (Delivered as part of Standard Care)
Description: Northern Hemisphere Influenza Vaccine 2017/18 (Delivered as part of Standard Care)
Study: NCT03017469

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ARISE
Description: 1. Full day (7.5 hours) workshop consisting of a resilience-focused seminar facilitated by our Employee Assistance Provider (EAP) \[Shepell\], an introduction to hospital based resources including EAP and health and wellness offerings, and an introduction to self-care and self-care techniques including yoga and stretches, stress relief using the senses and mindfulness~2. Half day (3.75 hours) workshop focusing on the following self-care techniques: mindfulness, yoga and stretching, and creative and reflective reading and writing~3. Peer support through social media engagement (closed Facebook group) for 3 months post-intervention participation~4. Five online, instructor-guided mindfulness sessions (Zoom)
Study: NCT04421469

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triprilimab(JS001)
Description: 1. JS001 240mg d1, gemcitabine(1g/m²),d1,8 + nedaplatin (80-100mg/m²),d2,q3w,6cycles.The curative effect was evaluated every 2 cycles.If the therapeutic evaluation was SD,the chemotherapy scheme was changed;~2. Local treatment of active lesions(including radiotherapy and/or radiofrequency ablation);~3. JS001 maintenance treatment.
Study: NCT01837940

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Galactooligosaccharide (GOS) and rhamnose in a powder formulation

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus reuteri DSM 17938
Description: Lactobacillus reuteri DSM17938, Galactooligosaccharide (GOS), rhamnose in a powder formulation
Study: NCT00963625

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Embryo cryopreservation
Description: Cohort cryopreserved as bipronuclear (2pn) oocytes, then thawed and cultured to the blastocyst stage before transfer to the uterus.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fresh blastocyst transfer
Description: Fresh blastocyst transfer following cycle of controlled ovarian stimulation.
Study: NCT03773835

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK3486
Description: Mmanual IV bolus injection completed in 1 minute.
Study: NCT00925977

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin Glargine + Insulin Apidra
Description: 12 wees treatment with Insulin Glargine + Insulin Apidra
Study: NCT03602443

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Waitlist Control
Description: Participants randomized to this arm will be followed for the 4-week time period. We will track engagement in any daily exercise (not therapy services) through self-report.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Waitlist Control
Description: Participants randomized to this arm will be followed for the 4-week time period. We will track engagement in any daily exercise (not therapy services) through self-report.
Study: NCT04309318

Intervention type: PROCEDURE
Intervention: Low pneumoperitoneum (10-12 mmHg) pressure range group
Description: Patients who have elective laparoscopic surgery with 10-12 mmHg intra-abdominal pneumoperitoneum pressure

Intervention type: PROCEDURE
Intervention: High pneumoperitoneum (13-15 mmHg) pressure range group
Description: Patients who have elective laparoscopic surgery with 13-15 mmHg intra-abdominal pneumoperitoneum pressure
Study: NCT03776838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Fentanyl guided by SoC+NOL
Description: Predeterminated bolus of IV Fentanyl will be given at the induction of anesthesia (2 mcg/kg), at the time of incision (1 mcg/kg). During surgery, administration of 0.5 mcg/kg of IV Fentanyl will be administred following a pre determinated algorithm based on NOL index + heart rate + mean arterial blood pressure variations.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Fentanyl guided by SoC
Description: Bolus of IV Fentanyl at the discretion of a physician will be given at the induction of anesthesia, and at the time of incision. During surgery, administration of IV Fentanyl at the discretion of a physician will be administred following a pre determinated algorithm based on heart rate + mean arterial blood pressure variations.